Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (March 2015)
18 slides from Actinogen Medical's investor presentation, Mar 9, 2015
Slide 1: Developing Xanamem for Alzheimer's Dementia
Developing Xanamem™ for Alzheimer’s Dementia For personal use only Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015
Slide 2: Forward Statements
Forward Statements For personal use only This presentation has been prepared by Actinogen Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform
Slide 3: Actinogen Medical - Overview
Actinogen Medical - Overview For personal use only Developing a novel treatment for Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI) • Lead compound Xanamem™ blocks production of cortisol – the stress hormone – in the brain. A novel mechanism of action Successful early development – Phas
Slide 4: Board and Management
Board and Management For personal use only A highly experienced Board and Management team with a wealth of drug development, commercialisation and clinical research expertise Martin Rogers • Biotechnology entrepreneur and executive Chairman • Chair and Non Executive Director of OncoSil (ASX:OSL), Ch
Slide 5: A significant, unmet need
A significant, unmet need For personal use only Alzheimer’s disease is emerging as one of the most significant health challenges of our time • A person develops AD almost every minute in the US¹ • AD cost the US healthcare system $US250 billion in 2013 • Estimated to increase to US$1 trillion by 205
Slide 6: AD consequence of a rapidly ageing population
AD consequence of a rapidly ageing population For personal use only Number of people aged 60 or over: World, • Affects nearly 36 million developed and developing countries, 1950-2050 patients worldwide¹ • In Australia, there are currently 320,000 AD sufferers – by 2050, this is expected to rise to c
Slide 7: The hallmarks of AD
The hallmarks of AD For personal use only Memory, language and abstract reasoning impairment with • brain shrinkage – particularly hippocampus and cortex • neuronal loss Normal • amyloid plaques • neurofibrillary tangles Alzheimer’s 7
Slide 8: Signs of AD
Signs of AD For personal use only Dementia is typically documented by decreasing performance on neuropsychological tests assessing memory, general knowledge, language, abstract reasoning and the ability to perform particular tasks requiring minimal skill: ‘ Please draw a clock. Put the hours on it a
Slide 9: Overview of Xanamem
Overview of Xanamem™ For personal use only Xanamem™ - under development as a treatment for Alzheimer's disease and its precursor Mild Cognitive Impairment • A novel mechanism of action blocking the production of cortisol in the brain • Excess cortisol (the stress hormone) has been shown to lead to r
Slide 10: Mechanism of action: a key differentiator
Mechanism of action: a key differentiator For personal use only Xanamem’s novel mechanism of action sets it apart from other AD treatments • The HSD1 enzyme activates cortisone, producing cortisol – the stress hormone • Xanamem™ blocks the HSD1 enzyme and prevents production of cortisol • Excess cor
Slide 11: Pre-clinical data
Pre-clinical data For personal use only Xanamem™- a highly selective HSD1 inhibitor in pre-clinical animal models. • Inhibition of HSD1 improves cognition in ageing and AD models • Inhibition of HSD1 reduces Aβ plaque burden and plasma Aβ in AD models 11
Slide 12: Clinical trials overview
Clinical trials overview For personal use only Second Phase 1 study in healthy volunteers underway • Trial conducted at Linear Clinical Research, Sir Charles Gairdner Hospital Perth, Western Australia. • 40 healthy volunteers enrolled across 3 studies • First study to confirm how the body absorbs an
Slide 13: Pipeline
Pipeline For personal use only Xanamem’s novel mechanism of action – blocking excess cortisol production – has many additional possible applications • Relevant to diseases of the central nervous and endocrine/metabolic systems • Assessing potential development opportunities in: – Cognitive dysfuncti
Slide 14: Financial profile
Financial profile For personal use only Key Corporate Data: Market Cap: $35 m Share Price $0.072 Cash as of 31 Dec $2.05 m 2014 Shares on issue 492 m Top Ten Shareholders Percentage Edinburgh Technology Fund Limited 9.78% JK Nominees Pty Ltd 7.05% Tisia Nominees Pty Ltd 6.83% Mr Martin Rogers 5.08%
Slide 15: Milestones
Milestones For personal use only Ethics Phase II efficacy Second approval study in patients Phase I Results for Phase I received with AD and Mild trial trial and final Cognitive preclinical studies Initiated Impairment EARLY-2015 MID-2015 2016 Final 1 of 2 Establishment of Phase II pre-clinica
Slide 16: Investment highlights
Investment highlights For personal use only • Xanamem™ a potential treatment for AD and its early symptomatic stage Mild Cognitive Impairment • Significant unmet need in a huge and growing global market • Novel mechanism of action, targeting the stress hormone cortisol – a key differentiator • Hypot
Slide 17: Contact details
Contact details For personal use only Head Office Level 10, 15-17 Young Street, Sydney, NSW, 2000 Telephone: +61 (02) 8964 7401 Facsimile: +61 (02) 8964 7588 Email: [email protected] Twitter: @billketelbey 17
Slide 18: Thank you and questions
For personal use only Thank you and questions
Actinogen Medical — Investor Presentation (March 2015) on 6ix